A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Trial Profile

A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Metformin (Primary) ; Antineoplastics
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 1 Oct 2016 to 1 Feb 2018.
    • 03 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2018.
    • 06 Jun 2017 Results (n=38) assessing the effect of metformin as a cancer stem cell targeting agent in patients with advanced stage epithelial ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top